findmyKOL
Clinical trialNCT04887792RecruitingPhase 1/PHASE2Interventional

Acetazolamide for Treatment Resistant Schizophrenia

SponsorVishwajit Nimgaonkar, MD PhDEnrollment60Schizo Affective DisorderSchizophrenia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

India
  • St John'S Medical College Hospital

    Bangalore, India

    Anil Kakunje, M.D.Ashok Mysore, M.D.Smita Deshpande, M.D.
    Recruiting
United States
  • University of Pittsburgh

    Pittsburgh, Pennsylvania, United States

    Ian Conner, M.D.Konasale Prasad, M.D.Madhavi K Ganapathiraju, Ph.D.Maribeth A Wesesky, BPSRoy KN Chengappa, M.D.Satish Iyengar, Ph.D.
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Feb 2022
Primary completion
30 Dec 2027
Completion
30 Jun 2028
Last update posted
7 Jul 2026
Registered enrollment
60
Registry id
NCT04887792

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.